KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kiniksa Pharmaceuticals International, plc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$79.48+0.89 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $6.55B
- P/E (TTM)
- 88.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
88.5%
Operating margin
11.4%
Net margin
8.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +60.1% | +45.5% | – | – | |
| Gross profit | +65.6% | +44.9% | – | – | |
| Operating income | – | +99.2% | – | – | |
| Net income | – | -31.5% | – | – | |
| EPS, diluted | – | -33.9% | – | – | |
| Free cash flow | +436.8% | +188.1% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -60.1% | 11.7% | |
| Return on assets | – | -53.4% | 8.8% | |
| Current ratio | – | 10.46 | 3.79 | |
| Inventory turnover | – | – | 1.9× | |
| Capex to revenue | – | – | 0.2% | |
| Diluted shares | – | 62M | 79M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Kiniksa Pharmaceuticals International generated $309.08M from operations and spent $2.50M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$309.08M
Used
$2.50M
Capital expenditure$2.50M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.7%
×Asset turnover1.01×
×Equity multiplier1.34×
=Return on equity, FY202511.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.7% | 1.01× | 1.34× | 11.7% |
| FY2024 | -10.2% | 0.76× | 1.26× | -9.8% |
| FY2023 | 5.2% | 0.55× | 1.18× | 3.4% |
| FY2022 | 83.3% | 0.64× | 1.19× | 63.1% |
| FY2021 | -409.7% | 0.13× | 1.17× | -63.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$59.01M
- Cash generatingOperating cash flow above zero$137.99M
- Return on assets improvedROA up on the prior year-8.2% → 10.2%
- Earnings backed by cashOperating cash flow above net income$137.99M vs $59.01M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.30 → 3.79
- No dilutionShare count did not rise71M → 79M
- Gross margin improvedGross margin up on the prior year85.61% → 88.54%
- More efficientAsset turnover rose0.80 → 1.17